Latest Conference Articles

January 15th 2021, 9:22pm

Gastrointestinal Cancers Symposium (ASCO GI)

Satya Das, MD, MSCI, discusses the results of a clinical score analysis in patients with neuroendocrine tumors.

January 15th 2021, 9:18pm

Gastrointestinal Cancers Symposium (ASCO GI)

John H. Strickler, MD, discusses the rationale for the phase 2/3 MOUNTAINEER-02 trial in HER2-positive gastric/gastroesophageal junction cancer.

January 15th 2021, 9:15pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - Combination treatment with adjuvant S-1 and docetaxel led to an estimated 29% reduction in the risk of relapse compared with S-1 alone in patients with stage III gastric cancer.

January 15th 2021, 8:08pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - Anlotinib, a multitarget kinase inhibitor, was found to significantly improve progression-free survival with a manageable safety profile when used in Chinese patients with refractory metastatic colorectal cancer.

January 15th 2021, 8:01pm

January 15, 2021 - One-year overall survival was found increased the longer that patients with metastatic pancreatic ductal adenocarcinoma remained on treatment with liposomal irinotecan plus 5-fluorouracil/leucovorin.

January 15th 2021, 7:15pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - Pembrolizumab with trastuzumab and the combination of cisplatin and capecitabine appeared effective in treating HER2-positive advanced gastric and gastroesophageal junction cancer, regardless of a patient’s PD-L1 status.

January 15th 2021, 7:13pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - Patients with esophageal/gastroesophageal cancer treated with nivolumab had improved esophageal-specific and general quality of life, although trends were similar in those treated with placebo.

January 15th 2021, 6:12pm

January 15, 2021 - A novel combination comprised of camrelizumab and apatinib was found to have promising clinical efficacy with an acceptable safety profile when used as a second-line treatment in patients with esophageal squamous cell carcinoma.

January 15th 2021, 5:10pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - Pembrolizumab plus lanreotide elicited a stable disease rate of 39% in patients with advanced, progressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), according to findings from the phase 1b/2 PLANET study.

January 15th 2021, 5:01pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - A novel artificial intelligence-based search tool made it easier for patients to find and understand cancer clinical trials, while also offering more clarity on how to enroll in them

January 15th 2021, 4:55pm

Gastrointestinal Cancers Symposium (ASCO GI)

January 15, 2021 - Findings from an analysis determined that stage 4 gastrointestinal stromal tumors were rare and led to hepatic metastases, although overall survival was up to 51% at 5 years.

January 15th 2021, 4:40pm

January 15, 2021 - Pembrolizumab (Keytruda) in combination with capecitabine and bevacizumab (Avastin) was found to show encouraging tolerability when used in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC), according to data from a phase 2 trial (NCT03396926) presented during the 2020 Gastrointestinal Cancers Symposium.

December 14th 2020, 10:30pm

PER® International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application

The emergence of checkpoint inhibitors has transformed the second-line treatment of patients with metastatic bladder cancer. However, questions regarding the utility of immunotherapy in the frontline setting remain unanswered, leaving chemotherapy as the standard-of-care option.

December 14th 2020, 9:33pm

PER® International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application

Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.

December 14th 2020, 9:30pm

PER® International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application

Jeffrey S. Weber, MD, PhD, discusses the toxicities associated with immunotherapy in lung cancer.

December 14th 2020, 9:00pm

PER® International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application

Checkpoint inhibitors have failed to improve progression-free survival and overall survival as second-line therapy and maintenance therapy in small cell lung cancer, but this class of agents continue to show encouraging activity worthy of a paradigm shift up front.

December 14th 2020, 7:35pm

PER® International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application

Mario Sznol, MD, discusses the critical importance of being aware of the immune-related toxicities that could arise when treating patients with cancer, along with the best ways to manage them.

December 14th 2020, 4:35pm

San Antonio Breast Cancer Symposium

December 14, 2020 - The combination of neratinib and capecitabine showed a 34% reduction in the risk of disease progression or death compared with lapatinib and capecitabine in patients with HER2-positive breast cancer who had central nervous system metastases at baseline.

December 12th 2020, 1:18am

San Antonio Breast Cancer Symposium

Erika P. Hamilton, MD, discusses the mechanism of action of OP-1250 in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

December 12th 2020, 1:06am

San Antonio Breast Cancer Symposium

Nadia Harbeck, MD, PhD, discusses Ki-67 as a biomarker for identifying patients with high-risk early breast cancer who received treatment on the monarchE trial.